143 related articles for article (PubMed ID: 36884358)
1. A multidimensional pan-cancer analysis of DCAF13 and its protumorigenic effect in lung adenocarcinoma.
Wei S; Lu K; Xing J; Yu W
FASEB J; 2023 Apr; 37(4):e22849. PubMed ID: 36884358
[TBL] [Abstract][Full Text] [Related]
2. DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma.
Wei S; Xing J; Chen J; Chen L; Lv J; Chen X; Li T; Yu T; Wang H; Wang K; Yu W
J Exp Clin Cancer Res; 2024 Jan; 43(1):3. PubMed ID: 38163876
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
4. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
7. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
8. The Pan-Cancer Crosstalk Between the
Xie R; Yuan M; Jiang Y
Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
[No Abstract] [Full Text] [Related]
9. Prognostic value and immunological role of FOXM1 in human solid tumors.
Wei G; Yang X; Lu H; Zhang L; Wei Y; Li H; Zhu M; Zhou X
Aging (Albany NY); 2022 Nov; 14(22):9128-9148. PubMed ID: 36435510
[TBL] [Abstract][Full Text] [Related]
10. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
11. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
12. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
13. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
14. Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistance.
Chen W; Li X; Jiang Y; Ni D; Yang L; Wu J; Gao M; Wang J; Song J; Shi W
Sci Rep; 2023 Nov; 13(1):19209. PubMed ID: 37932473
[TBL] [Abstract][Full Text] [Related]
15. [N
Wang J; Zhao X; Lu Y; Fan D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Dec; 38(12):1069-1077. PubMed ID: 36585228
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
18. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
Yang W; Han B; Chen Y; Geng F
Aging (Albany NY); 2022 Aug; 14(15):6316-6337. PubMed ID: 35963646
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.
Wang Y; Chen R; Zhang J; Zeng P
PLoS One; 2024; 19(4):e0299949. PubMed ID: 38635758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
